ImmunityBio (NASDAQ:IBRX) Stock Purchase Reported by Rep. Lisa C. McClain

Representative Lisa C. McClain (Republican-Michigan) recently bought shares of ImmunityBio, Inc. (NASDAQ:IBRX). In a filing disclosed on October 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in ImmunityBio stock on September 30th. The trade occurred in the Representative’s “CHARLES SCHWAB 401K (HANTZ) > SCHWAB 824” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 9/30/2026.
• Sold $15,001 – $50,000 in shares of Seagate Technology (NASDAQ:STX) on 9/30/2026.
• Purchased $1,001 – $15,000 in shares of Caterpillar (NYSE:CAT) on 9/28/2026.
• Purchased $1,001 – $15,000 in shares of ImmunityBio (NASDAQ:IBRX) on 9/28/2026.
• Purchased $15,001 – $50,000 in shares of Olin (NYSE:OLN) on 9/14/2026.
• Purchased $1,001 – $15,000 in shares of Novagold Resources (NYSEAMERICAN:NG) on 9/14/2026.
• Purchased $15,001 – $50,000 in shares of Transocean (NYSE:RIG) on 9/14/2026.
• Purchased $15,001 – $50,000 in shares of CACI International (NYSE:CACI) on 9/14/2026.

ImmunityBio Stock Performance

Shares of NASDAQ:IBRX opened at $9.91 on Thursday. ImmunityBio, Inc. has a 52 week low of $1.95 and a 52 week high of $12.43. The firm has a market cap of $10.50 billion, a PE ratio of -10.22 and a beta of 0.02. The firm’s fifty day moving average is $8.48 and its 200-day moving average is $7.94.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The company had revenue of $51.24 million during the quarter, compared to analyst estimates of $49.70 million. Sell-side analysts forecast that ImmunityBio, Inc. will post -0.44 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on IBRX shares. Jefferies Financial Group reissued a “buy” rating and issued a $14.00 price objective on shares of ImmunityBio in a research note on Wednesday. Piper Sandler reiterated an “overweight” rating and issued a $16.00 target price on shares of ImmunityBio in a report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ImmunityBio in a report on Tuesday, October 6th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $16.00.

Institutional Trading of ImmunityBio

Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. boosted its stake in shares of ImmunityBio by 29.4% in the 2nd quarter. BlackRock Inc. now owns 34,083,262 shares of the company’s stock worth $298,399,000 after buying an additional 7,736,819 shares during the last quarter. State Street Corp increased its position in shares of ImmunityBio by 20.8% during the 2nd quarter. State Street Corp now owns 21,398,438 shares of the company’s stock valued at $187,343,000 after purchasing an additional 3,690,335 shares during the last quarter. Bank of America Corp DE increased its position in shares of ImmunityBio by 2.7% during the 1st quarter. Bank of America Corp DE now owns 2,447,843 shares of the company’s stock valued at $18,775,000 after purchasing an additional 65,340 shares during the last quarter. SEB Asset Management AB bought a new stake in shares of ImmunityBio during the 1st quarter worth $18,770,000. Finally, Private Advisor Group LLC boosted its holdings in shares of ImmunityBio by 923.5% in the 1st quarter. Private Advisor Group LLC now owns 1,648,556 shares of the company’s stock worth $12,644,000 after buying an additional 1,487,482 shares during the last quarter. Institutional investors own 8.58% of the company’s stock.

Insider Transactions at ImmunityBio

In other news, Director Barry Simon sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $10.75, for a total transaction of $268,750.00. Following the completion of the sale, the director owned 2,777,788 shares in the company, valued at $29,861,221. This trade represents a 0.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Cheryl Cohen sold 81,056 shares of the firm’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $10.50, for a total value of $851,088.00. Following the completion of the sale, the director directly owned 100,309 shares of the company’s stock, valued at $1,053,244.50. This represents a 44.69% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 66.10% of the stock is owned by insiders.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

About ImmunityBio

ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body’s immune system against cancer and infectious diseases. The company combines cytokine-based therapies, vaccines, cellular therapies and other immune-modulating technologies in an effort to create durable treatment responses.

Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist immune stimulator.